Nxera Pharma Co. Ltd announces that its operating business Nxera Pharma Korea has entered into an exclusive supply and distribution agreement with Handok Inc. to commercialize PIVLAZ™ 150 mg in South Korea.
Nxera Pharma Co. Ltd announces that its operating business Nxera Pharma Korea has entered into an exclusive supply and distribution agreement with Handok Inc. to commercialize PIVLAZ™ 150 mg in South Korea.